ImmuCell Corporation Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ImmuCell Corporation (ICCC) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $95.72 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-13
- ImmuCell Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- ImmuCell Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- ImmuCell Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ImmuCell Corporation right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $381.90K.
- ImmuCell Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ImmuCell Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $103.11K, a 95.83% decline from fiscal 2023.
- ImmuCell Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.47M, a 108.67% increase from fiscal 2022.
- ImmuCell Corporation right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $1.18M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $95.72K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 10-K · filed 2026-03-30 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $103.11K 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $103.11K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $381.90K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $381.90K derived: sum of 2 quarters · filed 2024-04-01 | $2.47M 10-K · filed 2024-04-01 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.09M 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $2.09M 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.18M 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $1.18M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |